Evidence map›Paper›PMID 34259963›Full record

ArticleAIDS and behavior2022

Delivering PrEP to Young Women in a Low-Income Setting in South Africa: Lessons for Providing Both Convenience and Support.

Tali Cassidy, Nelisiwe Ntuli, Charllen Kilani, Nikiwe Malabi, Bulelwa Rorwana, Tabitha Mutseyekwa, Rebecca O'Connell, Sarah Jane Steele, Zee Ndlovu, Tom Ellman and 4 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in AIDS and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Tali CassidyMédecins Sans Frontières, Cape Town, South Africa. talicassidy@gmail.com.ORCID http://orcid.org/0000-0003-1268-3331
Nelisiwe NtuliMédecins Sans Frontières, Cape Town, South Africa.
Charllen KilaniMédecins Sans Frontières, Cape Town, South Africa.
Nikiwe MalabiMédecins Sans Frontières, Cape Town, South Africa.
Bulelwa RorwanaMédecins Sans Frontières, Cape Town, South Africa.
Tabitha MutseyekwaMédecins Sans Frontières, Cape Town, South Africa.
Rebecca O'ConnellMédecins Sans Frontières, Cape Town, South Africa.
Sarah Jane SteeleSouthern African Medical Unit, Cape Town, South Africa.
Zee NdlovuSouthern African Medical Unit, Cape Town, South Africa.
Tom EllmanSouthern African Medical Unit, Cape Town, South Africa.
Virginia de AzevedoCity Health Department, Cape Town, South Africa.
Colin PfaffMédecins Sans Frontières, Cape Town, South Africa.
Aurelie NelsonMédecins Sans Frontières, Cape Town, South Africa.
Laura Trivino DuranMédecins Sans Frontières, Cape Town, South Africa.
Médecins Sans Frontières · ZAHealth & Medical Publishing Group · ZACity of Cape Town · ZAWestern Cape Department of Health · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daily oral pre-exposure prophylaxis (PrEP) is a key tool in addressing high HIV incidence among young women, and breaking the cycle of transmission. From 2017 to 2020, Médecins Sans Frontières (MSF) offered PrEP, in conjunction with contraception and risk-reduction counselling, to women aged 18-25, in a government-run clinic in Khayelitsha, a low income high HIV prevalence area in South Africa. Drawing on clinical, quantitative, and qualitative interview data, we describe participants' experiences and engagement with the PrEP program, participant adherence (measured by TFV-DP levels in dried blood spots) over time, and the indirect benefits of the PrEP program. Of 224 screened and eligible participants, 164 (73.2%) initiated PrEP, with no large differences between those who initiated and those who did not. Overall, 47 (29%) completed 18 months follow-up, with 15 (9.1%) attending all visits. 76 (46.9%) participants were lost to follow-up, 15 (9.1%) exited when leaving the area, and 28.7% of exits happened in the first month of the study. We identified two different trajectories of PrEP adherence: 67% of participants had, on average, consistently low TFV-DP levels, with the remaining 33% having sustained high adherence. Few baseline characteristics predicted good adherence. The main reported barrier to taking PrEP was forgetting to take or travel with the pills. Encouragement from others declined as a reported facilitator from month 6 to 18 (family: 93.1% vs 77.6%, p = 0.016, friends: 77.6% vs 41.4%, p ≤ 0.001, partners: 62.1% vs 46.6%, p = 0.096, other PrEP users: 89.7% vs 74.1%, p = 0.020). Disclosure to friends and family in some cases opened dialogue around sex, and helped to educate others about PrEP. Self-reported sex with more than one partner, and sex without a condom, decreased significantly after enrolment (p < 0.001, p = 0.063). In the individual interviews, participants credited their PrEP experience with changing their behaviour. Recognising the challenges with, but overall benefits from a package of care that includes the option of PrEP, lessons drawn from this study can help maximise persistence on PrEP within resource constraints. PrEP providers need to address participants' need for both convenience and social support.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentAdultFemaleHumansMedication AdherenceSouth AfricaYoung AdultAnti-HIV AgentsAdherenceAfricaHIV preventionPre-exposure prophylaxisYoung women

Identifiers

PMID34259963
PMCPMC8786762
OpenAlexW3180958876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.